IV durvalumab

Phase 3Monoclonal antibody

AstraZeneca

IV durvalumab is one of 30 small molecule programs targeting Hairy Cell Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hairy Cell LeukemiaActive, not recruiting

Solid TumoursRecruiting

Hairy Cell LeukemiaPhase 3

Active, not recruiting

Solid TumoursPhase 1

Recruiting

Competition

Competitive Landscape

33 competitors in Hairy Cell Leukemia

#DrugCompanyPhaseTrials

Braftovi

Rituxan

7 3

Gazyva

Roche

Phase 2

2 4

Venclexta

AbbVie

Phase 2

1 5

Mektovi

Pfizer

Phase 2

1 6

Nipent

Pfizer

Phase 2

1 7

Leustatin

EMD Serono

Phase 2

4 8

Roferon-a

Roche

Phase 2

—9

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 2

3 10

Tylenol

KKenvue Brands

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Solid Tumours

NCT07391670

Q3 2029

Phase 1Recruiting

Solid Tumor

NCT07161414

Clinical

Trials by Indication[1]

Hairy Cell Leukemia1 trial

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01829711·80 enrolled

Solid Tumours1 trial

A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants With Solid Tumours

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07391670·40 enrolled

Solid Tumor1 trial

A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokinetics, and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ARTEMIDE-subQ)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07161414·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IV durvalumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV durvalumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV durvalumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

IV durvalumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2029

Trials by Indication[1]

Hairy Cell Leukemia1 trial

Solid Tumours1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News